Avelumab for advanced Merkel cell carcinoma in the Netherlands:a real-world cohort
Background Merkel cell carcinoma (MCC) is associated with high recurrence rates and poor survival when metastatic disease is present. The immune checkpoint inhibitor avelumab has shown high response rates (RRs) and durable responses in patients with advanced MCC (aMCC) in clinical trials. To date, only results from clinical trials, patients treated in an expanded access program and very small numbers of patients have been reported. In this study, detailed real-world efficacy and toxicity data of avelumab in patients with aMCC are reported. Methods Patients with aMCC treated in four dedicated r... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Reihe/Periodikum: | Levy , S , Aarts , M J B , Eskens , F A L M , Keymeulen , K B M , Been , L B , Grunhagen , D , van Akkooi , A , Jalving , M & Tesselaar , M E T 2020 , ' Avelumab for advanced Merkel cell carcinoma in the Netherlands : a real-world cohort ' , Journal for ImmunoTherapy of Cancer , vol. 8 , no. 2 , 001076 . https://doi.org/10.1136/jitc-2020-001076 |
Schlagwörter: | immunotherapy / skin neoplasms / programmed cell death 1 receptor / PROGNOSTIC-FACTORS / POLYOMAVIRUS / CHEMOTHERAPY / EPIDEMIOLOGY / EXPERIENCE |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26821026 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://cris.maastrichtuniversity.nl/en/publications/15cc957e-9b99-4ab1-ba86-30145e447265 |